Pfizer to begin clinical trials for a COVID-19 shot targeting Delta variant

  • Pfizer (NYSE:PFE) and its partner BioNTech (NASDAQ:BNTX) are planning to begin clinical studies for an updated version of their COVID-19 vaccine to target the Delta variant of the virus, Financial Times reports. In the post-market, the shares of the two vaccine makers are rising on the news.
  • Pfizer and BioNTech are in talks with the U.S. regulators over plans for the clinical trial which is expected to begin in August.
  • 'While we believe a third dose of [our vaccine] has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, we are remaining vigilant and are developing an updated version of the Pfizer-Covid-19 vaccine," Pfizer noted.
  • The development is likely to garner attention amid concerns over the efficacy of the current generation of COVID-19 vaccines as the prevalence of highly transmissible Delta variant rises.

    Over the current book year the total revenue from the company in New York City will be 73.51 billion USD (consensus estimates). This is rather significant more than 2021's revenue of 41.91 billion USD.

    Historical revenues and results Pfizer plus estimates 2021

    financiële analyse

    The analysts expect for 2021 a net profit of 21.19 billion USD. For this year the consensus of the result per share is a profit of 3.73 USD. The price/earnings-ratio therefore equals 11.01.

    Huge dividend Pfizer

    Per share the analysts are expecting a dividend of 1.58 USD per share. Pfizer 's dividend yield thus equals 3.85 percent. The average dividend yield of the pharmaceutical companies equals a moderate 1.39 percent.

    Pfizer 's market capitalization is around 227.17 billion USD. 23

    Historical stock prices Pfizer period 2007-2021

    fundamental data pfizer

    At 21.24 the stock trades 0 percent lower at 41.05 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

    • Other stock news
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Pfizer now in top highest dividend yields in America
    Pfizer to broaden RSV portfolio with deal to acquire ReViral for up to $525 million
    Analysts expect revenue increase Pfizer, quite high dividend
    DoD awards Pfizer $1.4B contract modification for 200M COVID vaccine doses for donation
    Pfizer awarded $3.5 billion contract by U.S. Army to produce COVID-19 vaccines
    India in discussions with Pfizer to obtain 50M doses of COVID-19 vaccine
    Sector news
    Analysts expect over 2023 revenue increase UCB
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Analysts: this year best year ever for Carl Zeiss Meditec
    Sanofi-Aventis now in top highest dividend yields in France
    Extreme dividend yield Novartis
    Pfizer now in top highest dividend yields in America
    2023 record year for Johnson & Johnson
    National news
    Intuitive Surgical's sales on record level according analysts' estimates
    Analysts are counting on record year NetFlix
    Analysts expect record sales CSX
    Analysts expect sales decline Carmax
    Analysts: more sales Fastenal
    ConAgra Brands is one of the top American dividend stocks
    Analysts anticipate for 2023 on revenue increase RF Industries
    Press news
    PlusPlus Capital Financial S.à r.l. receives court approval to start Reorganization process
    2024 ANNUAL GENERAL MEETING OF KUDELSKI SA
    General Meeting of Arbonia AG approves all motions
    Knorr-Bremse Acquires Alstom’s Rail Signalling Technology Business in North America
    Retrieve Medical Advances Healthcare Documentation in Louisiana with New Software Implementation
    SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.
    The Boston Beer Company Debuts First-of-its-Kind Non-Alc Beverage, General Admission, Available Now via Direct-to-Consumer Shipping
    Logoanalist
    Returns European stocks
    Crypto currencies information
    About us Network Partners
    Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-xBats
    ©2024 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo